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Abstract: Osteoarthritis (OA) is a degenerative condition that involves the production of inflammatory
cytokines (e.g., interleukin-1β (IL-1β), tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6))
that stimulate degradative enzymes, matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS)
resulting in articular cartilage breakdown. The presence of interleukin-1β (IL-1β) is one reason
for poor clinical outcomes in current cell-based tissue engineering strategies for treating focal early
osteoarthritic defects. Mesenchymal stem cells (MSCs) are a potential cell source for articular cartilage
regeneration, although IL-1β has been shown to inhibit in vitro chondrogenesis. In vivo, articular
chondrocytes reside under a low oxygen environment between 2–5% oxygen (physioxia) and have
been shown to enhance in vitro MSC chondrogenic matrix content with reduced hypertrophic marker
expression under these conditions. The present investigation sought to understand the effect of
physioxia on IL-1β inhibited MSC chondrogenesis. MSCs expanded under physioxic (2% oxygen)
and hyperoxic (20%) conditions, then chondrogenically differentiated as pellets in the presence
of TGF-β1 and either 0.1 or 0.5 ng/mL IL-1β. Results showed that there were donor variations
in response to physioxic culture based on intrinsic GAG content under hyperoxia. In physioxia
responsive donors, MSC chondrogenesis significantly increased GAG and collagen II content, whilst
hypertrophic markers were reduced compared with hyperoxia. In the presence of IL-1β, these
donors showed a significant increase in cartilage matrix gene expression and GAG content relative
to hyperoxic conditions. In contrast, a set of MSC donors were unresponsive to physioxia and
showed no significant increase in matrix production independent of IL-1β presence. Thus, physioxia
has a beneficial effect on MSC cartilage matrix production in responsive donors with or without
IL-1β application. The mechanisms controlling the MSC chondrogenic response in both physioxia
responsive and unresponsive donors are to be elucidated in future investigations.
Keywords: cartilage; mesenchymal stem cells; chondrogenesis; hypoxia; interleukin-1β;
early osteoarthritis
1. Introduction
Osteoarthritis (OA) is a degenerative condition involving changes in articular cartilage matrix
resulting from the stimulation of matrix metalloproteinases (MMPs) and aggrecanases (a disintegrin
and metalloproteinase with thrombospondin motifs, ADAMTS) [1,2]. Focal degenerative defects in the
early stages of OA can be treated via autologous chondrocyte implantation (ACI), although studies have
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shown that there is a reduced improvement in clinical outcome scores and higher probability for graft
re-operation (two-fold failure rate) compared to traumatic defects [3,4]. A reason for the poor outcomes
in degenerative defects is the presence of inflammatory cytokines including interleukin-1alpha (IL-1α),
interleukin-1beta (IL-1β), and tumour necrosis factor-alpha (TNF-α) [5–12]. Specifically, in an early
OA situation, the presence of IL-1β has been shown to negatively influence the clinical outcome of ACI
for the treatment of degenerative cartilage lesions [3,4].
Alternative cell sources and culture conditions that can enable matrix production in spite of
cytokine presence are required to ensure successful clinical outcomes, especially for early OA lesions.
Mesenchymal stem cells (MSCs) are a suitable cell source for therapies due to their multilineage
differentiation potential, particularly towards the chondrogenic lineage [13,14]. However, IL-1β
has been shown to have an inhibitory effect on MSC chondrogenesis [15,16]. In vitro studies
examining methods to reduce the detrimental response have used anti-arthritic neutraceuticals
(e.g., curcumin, reservatrol, mangiferin), adenoviruses (e.g., lL-1 receptor antagonist) or mechanical
stimulation (e.g., ultrasound) [16–23]. The latter stimuli show that the negative effects of IL-1β on MSC
chondrogenesis can be reduced via environmental stimuli.
In vivo, articular chondrocytes reside under an oxygen tension between 2–5% oxygen that is
referred to as physioxia (the physiological oxygen tension) for these cells. Thus, the atmospheric
oxygen conditions (20% oxygen) of standard tissue culture incubators provide a hyperoxic state for
chondrocytes [24,25]. In vitro culture of articular chondrocytes under physioxia has been shown to
enhance cartilage matrix synthesis compared with hyperoxic culture [26–36]. Similar results were
found for MSCs [37–44]. However, whilst early data provided contradictory evidence as to whether
physioxia affects hypertrophy in MSCs, more recent data indicate a downregulation in the expression of
hypertrophic markers (e.g., MMP13 and collagen X) during physioxic MSC chondrogenesis [37,39–41].
The present investigation sought to understand the effect of physioxia on MSC chondrogenesis under
normal conditions and in the presence of IL-1β. Based on the previous literature, it was hypothesized
that physioxia would provide a beneficial response that would counter the effects of IL-1β-inhibited
MSC chondrogenesis.
2. Materials and Methods
2.1. Human MSC Isolation and Harvesting
Human bone marrow aspirates were isolated from the iliac crests of nine male patients (mean
age: 30 ± 11 years) undergoing knee arthroplasty and that required autologous bone grafting, sourced
from the iliac crest for the treatment of deep osteochondral defects, following informed consent of the
patients and using procedures that were approved by the local ethics committee (University Hospital
Regensburg; Ethic approval no.: Nr. 00/134) [45]. The mononuclear cell population from bone marrow
aspirates was counted and then seeded into flasks at a density of 1 × 105 cells/cm2 in low glucose
Dulbecco’s Modified Eagle medium (DMEM; Invitrogen, Karlsruhe, Germany) supplemented with 10%
(v/v) foetal bovine serum (FBS; PAN Biotech, Aidenbach, Germany), 1% (v/v) penicillin-streptomycin
(Invitrogen) and 5 ng/mL basic fibroblastic growth factor (bFGF; Peprotech, Hamburg, Germany).
Flasks were cultured in parallel in either a standard cell culture incubator at 20% oxygen, 5% CO2
and 70% N2 or a low oxygen incubator (ThermoFisher Scientific, Regensburg Germany) set at 2%
oxygen, 5% CO2 and 93% N2. For this manuscript, hyperoxia refers to 20% oxygen, whilst 2% oxygen
is termed as physioxia [24,39] The first media change was performed after 5 days and then media
was replenished twice a week until trypsinisation at 80% confluence and further passaged. Previous
publications using this method of isolation have demonstrated that the MSC population has a negative
expression of CD34, CD45 and CD19, whilst they showed positive expression of CD44, CD73 CD90,
CD105 and CD166 [37,46–48]. Cells were used for experiments at no later than passage 3.
Cells 2019, 8, 936 3 of 17
2.2. Chondrogenic Differentiation
Monolayer-expanded MSCs cultured under either hyperoxia or physioxia were used to form pellet
cultures as previously described [14]. In brief, pellets were formed by centrifuging 2× 105 MSCs at 250×
g for 5 min in 300 µL chondrogenic medium in polypropylene V-bottom 96-well plates. Chondrogenic
media consisted of serum-free high-glucose DMEM containing 10 ng/mL TGF-β1 (R&D systems),
100 nM dexamethasone, 50 µg/mL ascorbic acid-2-phosphate (all Sigma-Aldrich, Steinheim, Germany),
1 mM sodium pyruvate (Invitrogen) and 1% ITS (PAN Biotech GmbH, Aidenbach, Germany). An
initial experiment was performed to observe the effect IL-1β on MSC chondrogenesis. Hyperoxic
MSC chondrogenic pellets were cultured in the presence of 0.1, 0.5, 1 and 10 ng/mL interleukin-1beta
(IL-1β; Peprotech). The range of concentrations chosen for the study were based on previous literature
regarding the levels of IL-1β during osteoarthritis [8]. Following this study, chondrogenic media
supplemented with either 0.1 or 0.5 ng/mL IL-1β were applied to both hyperoxic and physioxic MSC
pellets. Pellets were then cultured under their respective expansion oxygen conditions for 21 days with
media changes performed every 2–3 days. In the case of physioxia pellets, media was pre-equilibrated
in a physioxia incubator prior to replenishment.
2.3. Wet Weight and GAG Assay
After 21 days in culture, the wet weight of pellets was measured. Media was collected at each
feeding during the culture period and included in the GAG measurements. Triplicate pellets from each
group were then digested with 150 µg/mL papain in PBS, pH 6.0, containing 8 mM sodium EDTA,
6 mM L-cysteine (all Sigma-Aldrich). Sulfated glycosaminoglycan (GAG) and DNA content were
quantified using 1,9-dimethylene blue (DMMB) and Picogreen (Quant-iT dsDNA; Invitrogen, Carlsbad,
CA, USA) assays, respectively. Digested pellet GAG and collected supernatant were quantified against
a standard curve generated using bovine chondroitin sulphate A (Sigma-Aldrich) diluted in either
DMEM or papain buffer as standard in serial dilution. DMMB dye (18 µg/mL in 0.5% ethanol, 0.2%
formic acid, 30 mM sodium formate, pH 3) was added to standards and samples and absorbance
measured at 575 nm (Tecan, Crailsheim, Germany). DNA content in pellet digests was quantified
using Quant-iT dsDNA assay according to manufacturers’ instructions.
2.4. Collagen I and II ELISA
Six pellets per condition were taken from culture on day 21 and homogenized using a PreCellys
homogenizer (Bertin Instruments, Montigny le Bretonneux, France), then digested using 10 mg/mL
pepsin in 0.05 M acetic acid, 0.5 M NaCl, pH 2.9 with continuous shaking at 4 ◦C for 48 h. Subsequent
steps and ELISA were performed according to manufacturer’s protocol (Type I Collagen detection kit,
Type II Collagen detection kit; both from Chondrex, Redmond, WA, USA).
2.5. Histology and Immunohistochemistry
Pellets were fixed in 4% PBS buffered paraformaldehyde, rinsed briefly in PBS and then incubated
in increasing sucrose concentrations (10–30%). Pellets were photographed with an optical microscope
(PL2000, Optech, Germany) and then embedded in Tissue-Tek (Sakura, Zoeterwnde, The Netherlands).
Embedded pellets were cryosectioned at 10 µm with a HM500 OM cryotome (Microm, Berlin, Germany).
Sulphated glycosaminoglycan content was observed by histochemical staining with DMMB (0.05%
1,9-dimethylmethylene blue, 0.5% ethanol, 0.2% formic acid, 30 mM sodium formate, pH 3).
Sections used for immunohistochemistry were rehydrated and antigen retrieval was performed
at room temperature. For collagen II (Calbiochem, Darmstadt, Germany) and MMP-13 (Abcam,
Cambridge, UK), sections were treated with 3 mg/mL pepsin (Sigma-Aldrich) in 1× citric/phosphate
McIlvaine buffer for 15 min. Sections used for collagen X (X53, ThermoFisher Scientific) staining were
treated with 1 mg/mL hyaluronidase in PBS (pH 5) for 60 min at 37 ◦C followed by pepsin treatment as
previously described. All sections were blocked with a blocking buffer (10% goat serum in 1× PBS
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(supplemented with 10% FBS for collagen II antibody)) for 1 h and then probed for human collagen II
(mouse monoclonal antibody, 1:200; Calbiochem), MMP-13 (rabbit polyclonal antibody, 1:200) and
collagen X (mouse monoclonal antibody, 1:50) in blocking buffer during overnight incubation with
gentle rocking. Following this, sections were washed and then secondary antibodies, fluorescein (FITC)
conjugated anti-rabbit IgG (1:200) and fluorescein (FITC) conjugated anti-mouse IgG (1:200) (Jackson
Immuno Research, Cambridge, UK) diluted in blocking buffer were applied and incubated for 1 h.
Slides were incubated with 4,6-diamidino-2-phenylindole (DAPI; 1:100,000 in PBS) for 5 min and then
mounted with Mowiol anti-fading media and imaged using an Olympus XC10 camera on an Olympus
BX61 fluorescence microscope (Olympus, Japan).
2.6. Gene Expression Analysis
RNA was extracted from a pool of six pellets for each condition or treatment. Pellets were snap
frozen, QIAzol (Qiagen, Hilden, Germany) added and then homogenized using a PreCellys system
homogenizer. Solution was removed and RNA was isolated using QIAzol method according to the
manusfacturer’s instructions. Samples were purified and genomic DNA removed via RNeasy
Mini kit (QIAGEN) according to manufacturers’ instructions. Total RNA was quantified and
200 ng was reverse-transcribed using Transcriptor first strand kit (Roche, Mannheim, Germany).
Quantitative polymerase chain reaction (qPCR) of chondrogenic genes (listed in Table 1) was
performed using Real Time PCR Ready Custom designed plates (BioRad Laboratories, Munich,
Germany) according to the manufacturer’s instructions [49]. qPCR reactions were performed using
a Biorad CFX96 system (Biorad). Results were analysed using the ∆∆Ct method and normalized
to the ribosomal protein 13a (RPL13a)—the most stably expressed of the three housekeeping genes
(hypoxanthine phosphoribosyltransferase (HPRT), Proteasome subunit beta type-4 (PSMB4) and
RPL13a) evaluated [50]. Gene expression in physioxia was calculated as fold change from that
measured under hyperoxia.
Table 1. List of chondrogenic genes used in custom PCR plates.
Transcription Factors Cartilage Matrix
L-SOX5
L-SOX6
SOX9
Aggrecan (ACAN)
Chondromodulin-1 (LECT1)
Cartilage oligomeric matrix protein (COMP)
Collagen type I α1 (COL1A1)
Collagen type II α1 (COL2A1)
Collagen type VI α1 (COL6A1)
Collagen type IX α1 (COL9A1)
Collagen type XI α2 (COL11A2)
Lysl Oxidase (LOX)
Lubricin (PRG4)
Matrillin-3 (MATN3)
Perlecan (HSPG2)
Versican (VCAN)
Transforming growth factor-β receptors Hypertrophy
TGF-β receptor I (TGFBR1)
TGF-β receptor II (TGFBR2)
Collagen type X α1 (COL10A1)
MMP-9
MMP-13
ADAMTS-4
ADAMTS-5
RUNX2
2.7. Statistical Analysis
All statistical analysis was performed using Graphpad Prism v7 (GraphPad, La Jolla, CA, USA). A
comparison of pellet wet weight, GAG and collagen II content between hyperoxia and physioxia was
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performed using two-way ANOVA with Tukey post-hoc test, with significance set at p < 0.05. Gene
expression data was calculated as fold change in physioxia relative to hyperoxia either with or without
IL-1β and then analysed using a Mann-Whitney test with significance set at p < 0.05.
3. Results
3.1. IL-1β Shows a Dose Dependant Decrease in Chondrogenic MSC Pellet Wet Weight and GAG Content
To understand the effect and choose appropriate conditions for examination under physioxia,
IL-1β concentrations ranging from 0.1–10 ng/mL were applied to chondrogenic MSCs under hyperoxia.
Results showed a significant decrease in both pellet wet weight and GAG content in the presence of
IL-1β relative to control chondrogenesis at concentrations above 0.1 ng/mL (Figure 1a,b; * p < 0.05).
There were no significant differences in wet weight or GAG content between pellets subjected to
concentrations above 0.5 ng/mL IL-1β. Macroscopic and DMMB histological images correlated with
these results, whereby at 0.1 ng/mL IL-1β, pellets were smaller but stained for glycosaminoglycans
within the matrix. At concentrations at or greater than 0.5 ng/mL IL-1β, there was no GAG deposition
in the pellet and all were of similar size (Figure 1c). Thus, 0.1 and 0.5 ng/mL IL-1β concentrations were
used for physioxia experiments.
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Figure 1. IL-1β dose response under hyperoxic conditions during chondrogenesis, examined for pellet
(a) wet weight and (b) GAG content. Box plots represent median ± I.Q.R; n = 3–12 donors; * p < 0.05;
(c) Representative macroscopic and DMMB-stained chondrogenic pellets under the range of IL-1β
concentrations used.
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3.2. Physioxia Alone Enhances MSC Chondrogenic Matrix Expression and Content
MSC chondrogenesis without the presence of IL-1β was first performed to understand the basic
response under physioxia. Examination of all donors indicated a significant difference in matrix
production under physioxia, with respect to wet weight (p = 0.0004), GAG (p < 0.0001) and collagen II
(p = 0.0078) content (Figure 2a–c; * p < 0.05). The analysis demonstrated that some donors within the
cohort examined, did not respond to physioxia. A previous publication demonstrated that MSC donors
can be separated into two discrete groups, based on their GAG production under hyperoxia relative
to chondrocytes under the same conditions (Figure 2d) [39]. Using the data from the publication,
thresholds for high or low GAG donors (indicated by the dotted lines) were calculated and then used
to disseminate the donors into physioxia responsive and non-responsive donors (Figure 2d). Donors
that were either below or above the first threshold were known as low GAG donors or physioxia
responders, whereas those at or above the second threshold are described as high GAG or physioxia
non-responders. The latter may also be described as a donor with less than a two-fold increase in GAG
content under physioxia.
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Figure 2. Donor-dependent responses in pellet (a) wet weight, (b) GAG and (c) collagen II content
between hyperoxia and physioxia cultured chondrogenic pellets in the presence of IL-1β. Dotted lines
represent corresponding donors at hyperoxia and physioxia. Data are presented for nine independent
donors (* p < 0.05). (d) Pellet GAG content for chondrogenic pellets under hyperoxia and physioxia.
Dotted lines indicate threshold for low GAG and high GAG donors based on data from a previous
publication [39].
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In the cohort for this study, there were two non-responding donors (20% of all donors examined)
that showed no difference in pellet wet weight, GAG and collagen II content compared with hyperoxic
cultures (Figure 3a,c,e). This was supported by histological analysis of these pellets whereby, there
was no increase in pellet size, or enhancement in DMMB and collagen II staining under physioxia
(Figure 3b,d,f). In contrast, responders showed a significant increase in pellet wet weight and GAG
(eight-fold increase; both p < 0.0001) and collagen II content (three-fold increase; p = 0.0121) with
respect to hyperoxia (Figure 4a,c,e; * p < 0.05). In contrast, analysis of collagen I in these responsive
donors demonstrated that physioxic MSC chondrogenesis had a significantly reduced collagen I content
(four-fold decrease; p = 0.0022) compared to hyperoxic MSCs (Figure 4g: * p < 0.05). Furthermore, the
ratio between collagen II to collagen I was greater under physioxia (mean ratio: 15 ± 10) compared to
hyperoxic (mean ration: 1 ± 0.5) MSC chondrogenesis. Macroscopic, DMMB and collagen II histology
correlated with these results, whereby larger pellets, greater metachromasia and collagen II staining
was observed under these conditions (Figure 4b,d,f,h).
3.3. Pellet Wet Weight and GAG Content in IL-1β Inhibited Chondrogenesis Is Suppressed under Physioxia in
Responsive Donors
In non-responsive donors, physioxia did not significantly increase the wet weight, GAG and
collagen II content in IL-1β treated pellets with histological staining supporting these results (Figure 3).
In contrast, physioxia-responding donors had significantly higher wet weight (p = 0.0433) and GAG
content (p = 0.0267) in the presence of 0.1 ng/mL IL-1β relative to corresponding pellets in hyperoxia
(Figure 4a,c; * p < 0.05). Histological images supported these results, whereby pellet size and DMMB
staining were greater in physioxic conditions (Figure 3b,d). Interestingly, there was no significant
increase in collagen II content in IL-1β-treated pellets under physioxia, with histological images in
agreement with these findings (Figure 4e,f). Furthermore, there was a significant increase in collagen I
content compared to the respective control conditions, particularly under physioxia (0 vs. 0.1 ng/mL
IL-1β, p = 0.0118) and between 0 ng/mL and 0.1 ng/mL IL-1β under hyperoxia (p = 0.0092; Figure 4g,h).
Physioxia showed a tendency to reduce collagen I content in IL-1β-treated pellets compared to
hyperoxic pellets but there was no significant difference either on a protein level or staining between
corresponding IL-1β-treated conditions (Figure 4g,h).
3.4. Physioxia Enhances Gene Expression of Chondrogenesis-Associated Markers and Suppresses Markers for
Late Stage Hypertrophy
The gene expression for control and IL-1β-treated pellets in responsive donors was examined to
determine how cartilage transcription factors, TGF-β receptors, matrix (Figure 5) and hypertrophy
genes were regulated under physioxia (Figure 6). For these studies, only 0.1 ng/mL IL-1β pellets
were analysed due to the similar effects on physioxia on IL-1β chondrogenesis. Physioxic culture
promoted SOX gene expression (Figure 5a). Conducting chondrogenesis under physioxia also lowered
the negative effects of IL-1β, whereby cartilage transcription factors, SOX5, 6 and 9 and TGF-β receptor
I and II (for all genes stated, p = 0.0286) were all significantly upregulated for physioxic chondrogenesis
compared with hyperoxic cultured pellets (Figure 5b, * p < 0.05). Cartilage matrix protein genes
examined were also significantly upregulated under physioxia, with or without IL-1β (Figure 5c,d;
* p < 0.05) including aggrecan and collagen II that correlate with the protein data (Figures 2–4).
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Figure 4. Pellet (a) wet weight, (c) GAG, (e) collagen II and (g) collagen I content in physioxia
responsive donors in the presence of IL-1β. Box plot represent median ± I.Q:R: of n = 7 donors;
* p < 0.05. Representative (b) macroscopic, (d) DMMB, (f) collagen II and (h) collagen I-stained pellets
of a responsive donor under physioxia and hyperoxia.
Cells 2019, 8, 936 10 of 17
1 
 
 
Figure 5. Gene expression of (a,b) chondrogenic transcription factors and (c,d) cartilage matrix proteins
under physioxia for (a,c) control and in the presence of (b,d) 0.1 ng/mL IL-1β for physioxia responsive
donors. Data represents the fold change in expression of pellets cultured under (a,c) 0 ng/mL and (b,d)
0.1 ng/mL IL-1β physioxia relative to the corresponding conditions under hyperoxia. Data represent
mean ± S.D. of n = 4 physioxia responsive donors; * p < 0.05.
Analysis of hypertrophic markers in physioxia chondrogenesis showed that in both non-responsive
and responsive donors, there was a suppression in collagen X (Figure 6a,c) and MMP13 protein
expression (Figure 6b,d) under physioxic conditions, particularly under control and 0.1 ng/mL IL-1β,
whereas there was greater expression at the corresponding conditions under hyperoxia. However,
contrary to these results, the analysis of these early hypertrophic genes in responsive donors showed
an upregulation in collagen X and MMP-13 expression under physioxia, independent of the presence
of IL-1β, with collagen X (p = 0.0286) being significantly upregulated (Figure 6e,f; * p < 0.05). However,
physioxic chondrogenesis alone showed a significant downregulation in late-stage hypertophic markers,
specifically the aggrecanases (ADAMTS-4 and ADAMTS-5) and the osteogenic transcription factor,
RUNX2 (for all genes stated, p = 0.0286) (Figure 6e; * p < 0.05), whereas in the presence of IL-1β, there
was only minimal expression of these genes (Figure 6f: * p < 0.05).
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Figure 6. Representative images of chondrogenic pellet stained for (a,c) collagen X and (b,d) MMP-13
in physioxia (a,b) non-responsive and (c,d) responsive donors at control, 0.1 ng/mL or 0.5 ng/mL IL-1β.
Gene expression of (e,f) hypertophic genes under physioxia for (e) control and in the presence of (f)
0.1 ng/mL IL-1β for physioxia responsive donors. Data represent the fold change in the expression of
pellets cultured under (a) 0 ng/mL and (b) 0.1 ng/mL IL-1β physioxia relative to the corresponding
hyperoxic condition. Data represent mean ± S.D. of n = 4 physioxia responsive donors; * p < 0.05.
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4. Discussion
The aim of the present investigation was to understand how physioxia modulates MSC
chondrogenesis and specifically, its effect on IL-1β-inhibited chondrogenesis. Under control conditions,
there was found to be donors that were responsive and non-responsive to physioxic conditions
(Figure 2). In this instance, two non-responsive donors were found amongst those examined and
showed no difference in pellet wet weight, GAG and collagen II content under physioxia with or
without IL-1β presence (Figure 3). It was found that under both control and in the presence of
IL-1β, responsive donors demonstrated a significant increase in wet weight and GAG content that
corresponded to an upregulation in cartilage transcription factors and matrix genes under physioxic
conditions (Figures 4 and 5).
It has been well-established that physioxic conditions enhance the anabolic response in MSC
chondrogenesis [15,37,39–43,51,52]. Anderson et al. (2016) showed that the reaction under physioxia
is related to the GAG production under hyperoxia. Using the data from this publication, thresholds
for low and high GAGs were calculated and then used to separate donors accordingly. High GAG
donors or physioxia non-responders did not show an increase in GAG and collagen II content under
physioxia (Figure 3), whereas low GAG or physioxia responsive donors demonstrated significant
increases in GAG and collagen II deposition under physioxia with concomitant upregulation in
cartilage transcription factors and matrix genes, supporting the data from earlier studies (Figures 4
and 5) [15,37,39–43,51,52].
In both donor response types, collagen X and MMP13 protein levels were reduced under physioxia
compared to hyperoxia with or without IL-1β presence on day 21, despite an upregulation in gene
expression (Figure 6). However, on day 14, COL10A1 gene expression under physioxia was lower
compared to day 21 with a corresponding reduction in collagen X protein levels (supplementary Figure
S1). In comparison, day 14 hyperoxic pellets stained for collagen X in the matrix both with and without
the presence of IL-1β. These results indicate that physioxia delays the onset of hypertrophy in MSC
chondrogenesis, as protein expression occurs at a later time point. This has been demonstrated in a
previous publication, whereby protein expression for hypertrophic markers was shown on day 28
physioxic chondrogenic pellets and reduced compared to those under hyperoxia [53].
In the present investigation, physioxia responsive donors still had a significant increase in wet
weight and GAG content over pellets in hyperoxia when cultured in the presence of IL-1β, and gene
expression results were consistent with these data (Figures 4 and 5b,d). These data are supported by a
previous publication by Felka et al. (2009) under similar experimental conditions, whereby physioxia
helped to reduce the negative effects of IL-1β on MSC chondrogenesis, although this was a more limited
study that only performed gene expression and histological analysis [15]. Boeuf et al. (2012) showed
that the effects of IL-1β on MSC chondrogenesis included the stimulation of aggrecanolysis [54]. Our
study demonstrated that physioxia downregulated the aggrecanases, ADAMTS-4 and ADAMTS-5.
However, a concomitant rise in collagen II production in physioxia with IL-1β treatment was not seen.
TNF-α, another pro-inflammatory cytokine involved in OA, has been shown to induce collagen II
degradation via MMPs and that physioxia could reduce this effect. Furthermore, the described TNF-α
model also showed an increased GAG content and reduced ADAMTS expression under physioxia,
similar to the data shown in this study using IL-1β [34]. Thus, different cytokines initiate distinct
degenerative cascades that can be influenced by pro-anabolic stimuli. Models utilising multiple
cytokines (e.g., TNF-α, IL-6 and IL-13) would provide a more accurate analysis of OA progression and
methods to reduce its degenerative effect on MSC chondrogenesis [5–12].
An interesting finding within this study is that even in the presence of IL-1β, physioxia
non-responsive or high GAG donors did not show an increase in wet weight, GAG and collagen II
content under physioxia (Figure 2). In spite of the low donor number, the presence of donors that
are non-responsive to physioxia indicates that MSC chondrogenesis is a donor-dependant process.
Markers predicting whether a donor has an anabolic response under physioxia remain to be elucidated.
Furthermore, these non-responsive physioxia donors did not show an increase in GAG content or
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wet weight under physioxia in the presence of IL-1β, suggesting that there are discrete mechanisms
occurring between physioxia responsive and non-responsive donors both in the absence and presence of
IL-1β. A greater cohort of donors from the described groups is required to understand the mechanisms
controlling the response, both with respect to monolayer expansion and pellet culture.
A potential mechanism for restoring MSC chondrogenesis in the presence of IL-1β-inhibited
chondrogenesis is TGF-β receptor I/II, as these were upregulated under physioxia (Figure 5b) [55]. IL-1β
inhibition in chondrocytes has been shown to involve the loss of TGF-β receptor I/II activity, resulting
in downregulation of SOX9 [56,57]. [16]. Downstream of the receptor, IL-1β inhibits phosphorylation
of SMAD3/4 in TGF-β-stimulated chondrocytes, whilst concurrently enhancing the inhibitory SMAD7
pathway [58]. It may be postulated that physioxia restores SMAD3/4 phosphorylation in spite of
IL-1β presence and is a downstream pathway that rescues MSC chondrogenesis in the presence of
inflammatory cytokines. Studies using chondrocytes have also implicated the NF-κB pathway in
cartilage degeneration [16,56,58]. Wehling et al. (2009) demonstrated that silencing this pathway via
an adenoviral transduction of the suppressor of NF-κB abrogated TNF-α and IL-1β inhibited MSC
chondrogenesis and restored cartilage matrix production [16]. Both the TGF-β/SMAD and NF-kB
pathways are to be investigated in future studies.
The beneficial response induced by physioxia preconditioned MSC chondrogenesis in the presence
of IL-1β in responsive donors, means that this is a potential treatment option for focal OA defects.
Animal models that mimic post-traumatic or early OA situations are required to understand whether
physioxia preconditioned MSCs or chondrogenic implants can regenerate articular cartilage in a
clinical setting. In vivo studies using physioxia preconditioned MSC chondrogenic implants (MSCs
expanded and in vitro chondrogenically stimulated under physioxia) in animal models have focussed
on post-trauma models and shown both an improvement and no difference in cartilage regeneration
compared to hyperoxic MSCs [59,60]. In particular, Leitjen et al. (2014) showed that physioxia
preconditioned MSC chondrogenic implants produced more stable articular cartilage upon implantation
in a nude mouse model, whereas hyperoxic-preconditioned MSC chondrogenic implant became
vascularized and formed bone [41]. In contrast, studies using rabbit and sheep models showed no
difference in cartilage regeneration [59,60]. However, no studies have evaluated treatment in an early
OA situation. In vivo models reflecting this setting are currently in progress.
There are limitations in the present study that should be noted when evaluating the data. The
present study only utilised a hypoxia incubator for maintaining physioxic culture of MSCs and
chondrogenic pellets and was not kept continuously under a physioxic environment using a glove-box
culture hood. However, this and other investigations that have demonstrated the anabolic effects of
physioxia on MSC chondrogenesis, show an enhancement both with [39] and without [37] the use of a
hypoxia chamber. Furthermore, there are also no significant differences between 5% and 2% oxygen in
previous studies with respect to the beneficial effects of physioxia on chondrogenesis [61]. Thus, our
results are in keeping with the literature on physioxia MSC chondrogenesis.
In conclusion, there is a donor-dependant response in MSC chondrogenesis under physioxia,
whereby, in responsive donors, there was enhanced cartilage matrix production and a reduced
expression of late-stage hypertophic markers. In the presence of IL-1β, physioxia responsive donors
showed a significant enhancement in GAG content and an upregulation in cartilage-related genes
including cartilage-specific transcription factors and TGF-β receptors that enable MSC chondrogenic
restoration. The mechanisms involved in the different responses under physioxia with or without
IL-1β and evaluation of the cartilage formation by physioxia-preconditioned MSCs in animal models
are to be examined in future studies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/8/936/s1,
Figure S1, Collagen X mRNA expression in (a) control (0 ng/mL IL-1β) and (b) IL-1β treated pellets in physioxia
responsive donors on day 14 and 21. Data represents fold change in expression of pellets cultured under physioxia
relative to corresponding conditions under hyperoxia. Data represent mean ± S.D. of n = 4 physioxia responsive
donors; * p < 0.05. Representative images of collagen X staining on (c) day 14 and (d) 21.
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